Related Experiment Video
Updated: Jul 5, 2025
Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers
Published on: March 1, 2024
An update of predictive biomarkers related to WEE1 inhibition in cancer therapy
Zizhuo Wang1, Wenting Li2, Fuxia Li2
1Department of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China.
Purpose:
WEE1 is a crucial kinase involved in the regulation of G2/M checkpoint within the cell cycle. This article aims to comprehensively review the existing knowledge on the implication of WEE1 as a therapeutic target in tumor progression and drug resistance. Furthermore, we summarize the current predictive biomarkers employed to treat cancer with WEE1 inhibitors.
Methods:
A systematic review of the literature was conducted to analyze the association between WEE1 inhibition and cancer progression, including tumor advancement and drug resistance. Special attention was paid to the identification and utilization of predictive biomarkers related to therapeutic response to WEE1 inhibitors.
Results:
The review highlights the intricate involvement of WEE1 in tumor progression and drug resistance. It synthesizes the current knowledge on predictive biomarkers employed in WEE1 inhibitor treatments, offering insights into their prognostic significance. Notably, the article elucidates the potential for precision medicine by understanding these biomarkers in the context of tumor treatment outcomes.
Conclusion:
WEE1 plays a pivotal role in tumor progression and is a promising therapeutic target. Distinguishing patients that would benefit from WEE1 inhibition will be a major direction of future research.
Insights
WEE1 kinase inhibition shows promise for targeting tumor progression and overcoming drug resistance. Identifying predictive biomarkers is key to selecting patients who will benefit from WEE1 inhibitors in cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Cell Cycle Regulation
Background:
- WEE1 kinase is essential for regulating the G2/M cell cycle checkpoint.
- Dysregulation of WEE1 contributes to tumor development and acquired resistance to therapies.
Purpose of the Study:
- To review WEE1's role in tumor progression and drug resistance.
- To summarize predictive biomarkers for WEE1 inhibitor therapy.
- To explore WEE1 as a therapeutic target in oncology.
Main Methods:
- Systematic literature review.
- Analysis of WEE1 inhibition's impact on cancer progression.
- Identification of biomarkers for WEE1 inhibitor response.
Main Results:
- WEE1 is intricately involved in tumor growth and resistance mechanisms.
- Current predictive biomarkers for WEE1 inhibitor treatment are synthesized.
- Biomarker insights offer potential for precision oncology.
Conclusions:
- WEE1 is a significant factor in tumor progression and a viable therapeutic target.
- Identifying patient populations for WEE1 inhibition is a critical future research area.
Related Concept Videos
02:54Canonical Wnt Signaling Pathway
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:41Non-Canonical Wnt Signaling Pathways